Lungs News and Research

RSS

People with common form of lung cancer can benefit from nivolumab drug

In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.

1 Jun 2015

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Researchers from University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine will present data from several new studies, including a study evaluating a potential novel combination treatment for cancer patients with advanced solid tumors and a first-of-its-kind analysis of gene mutations in small cell lung cancer (SCLC), at the 51st American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.

1 Jun 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features.

1 Jun 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

1 Jun 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

UN's Global Road Safety Week aims at making roads safer

From 4 to 10 May, the world will be celebrating the UN's Global Road Safety Week under the theme 'Children and road safety', which follows a 10-year series of resolutions aimed at making roads safer.

1 Jun 2015

New way to evaluate brainstorms in newborn very premature infants

Giant strides have been taken in the early care of very premature infants in postnatal intensive care units during the past two decades. Doctors can now support the function of especially the lungs, heart and the circulatory system so as to guarantee the survival of most of even extremely premature infants.

1 Jun 2015

UT Southwestern Medical Center Performs its 500th Lung Transplant on Cystic Fibrosis Patient

A lung transplant to relieve Christopher Bryant Vera from devastating effects of cystic fibrosis marked the 500th lung transplant performed at UT Southwestern Medical Center, positioning the Center among an elite group of fewer than 25 in the country to achieve that benchmark.

30 May 2015

RPCI-led research team to share clinical results of entolimod drug at ASCO 2015

A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute (RPCI) will share results from the first clinical study of the anticancer effects of the novel agent entolimod at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting in Chicago.

30 May 2015

Newer anticoagulant medication may increase risk of GI bleeding in older patients

In a study released online in April in the BMJ, a team of researchers from Mayo Clinic, and other collaborators, showed that for older patients, particularly individuals greater than 75 years of age, the risk of gastrointestinal (GI) bleeding is 3 to 5 times higher when taking newer anticoagulant medications dabigatran or rivaroxaban compared to when using warfarin.

30 May 2015

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology.

30 May 2015

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Data to be presented at the 51st Annual Meeting of the American Society of Clinical Oncology suggest that the investigational immunotherapy MPDL3280A may double the likelihood of overall survival in the study period (HR=0.47), compared with docetaxel chemotherapy, in individuals with non-small cell lung cancer (NSCLC) who expressed the highest levels of PD-L1 (a receptor present on cancer cells).

30 May 2015

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.

30 May 2015

Airway granulocytes potential CF biomarker for fungal lung disease

Researchers have found that accumulation in the airways of CXCR4+ granulocytes is associated with chronic colonisation by the fungus Aspergillus fumigatus.

29 May 2015

Challenge remains for early COPD detection in primary care

Exhaled carbon monoxide testing in primary care has no effect on patient acceptance of screening for chronic obstructive pulmonary disease, research shows.

29 May 2015

‘Real-world’ sunitinib findings support trial results

Results of postmarketing follow-up in Japanese patients confirm the efficacy and safety profile of sunitinib in advanced renal cell carcinoma.

29 May 2015

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

29 May 2015

New research shows wide variation in organ donation rates across the country

More than 123,000 Americans are currently waiting for lifesaving organ transplants, but 21 patients die each day because there aren't enough organs to go around. New research shows wide variation in the number of eligible organ donors whose loved ones consent to organ donation across the country.

29 May 2015

Lungs News and Research

People with common form of lung cancer can benefit from nivolumab drug

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

UN's Global Road Safety Week aims at making roads safer

New way to evaluate brainstorms in newborn very premature infants

UT Southwestern Medical Center Performs its 500th Lung Transplant on Cystic Fibrosis Patient

RPCI-led research team to share clinical results of entolimod drug at ASCO 2015

Newer anticoagulant medication may increase risk of GI bleeding in older patients

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Airway granulocytes potential CF biomarker for fungal lung disease

Challenge remains for early COPD detection in primary care

‘Real-world’ sunitinib findings support trial results

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

New research shows wide variation in organ donation rates across the country

The ultimate guide to lung research tools and protocols eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News